Vimarsana
Biggest News Aggregation in the World

Steady Path News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Steady Path. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Steady Path Today - Breaking & Trending Today

Grant Will Expand Services At Hancock County Stabilization Center - Vimarsana News

Grant Will Expand Services At Hancock County Stabilization Center

(From Hancock County ADAMHS) Hancock County has been awarded a $550,000 federal Bureau of Justice grant to expand services at a local residential center that provides stabilization and recovery support services for those with mental health and substance use disorders. The 3-year grant comes through the Bureau’s Justice and Mental Health Collaboration Program. The Board

Source: wfin.com
2023 China Economic Data: GDP Grows 5.5% in First Half of the Year - Vimarsana News

2023 China Economic Data: GDP Grows 5.5% in First Half of the Year

H1 2023 China economic data shows a steady post-COVID recovery while slowing growth in May and June is raising calls for stimulus in H2.

NEXA Music's Top 24 Indian Indie Artists: KL Pamei, INGA, Huyana, Big Deal - Vimarsana News

NEXA Music's Top 24 Indian Indie Artists: KL Pamei, INGA, Huyana, Big Deal

The chosen singer-songwriters, producers and composers from the country-wide talent hunt and incubator discuss goals, experiences and meeting A.R Rahman

BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod - Vimarsana News

BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod

BPTH On Steady Path, Cancer Genetics On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod Read on. 1. Bio-Path On A Steady Path Bio-Path Holdings Inc. (BPTH) has been granted the third U.S. patent, expanding the protection of its DNAbilize platform technology that helps to deliver DNA therapeutics directly to cancer cells. In addition, the company is expected to be issued a patent related to its lead product candidate, Prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib, on February 23...